1Oparil S. Newly emerging pharmacologic differences in angiotensin Ⅱ receptor blockers [ J ]. Am J Hypertens ,2000,13 : 185.
2Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortahty in the losartan intervention for endpoint reduction in hypertension (LIFE) : a randomised trial against atenolol [ J ]. Lancet ,2002,359:995-1003.
3Morimoto S, Yutaka Y, Maki K, et al. Renal and vascular protective effects of telmisartan in patients with essential hypertension[ J]. Hypertens Res,2006,29(8):567-572.
4Conlin PR, Spence JD, Williams B, et al. Angiotensin Ⅱ antagonists for hypertension : are there differences in efficacy [ J ] ? Am J Hypertens, 2000, 13 : 418- 426.
5Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension[J].J Clin Hypertens (Greenwich) ,2007,9(3) :187-195.
6Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan [ J ]. Am J Cardiovasc Drugs, 2005, 5:41-50.
7Kakuta H,Sudoh K, Sasamata M, et al. Telmisartan has the strongest binding affinity to angiotensin Ⅱ type 1 receptor: comparison with other angiotensin Ⅱ type 1 receptor blockers[ J]. Int J Clin Pharmacol Res,2005,25( 1 ) :4-1-46.
8Pitt B,Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure[ J]. Lancet, 1997,349:747-752.
9Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure[ J]. N Engl J Med,2001,345 : 1667-1675.
10Julius S, Kjeldsen ES, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine : the VALUE randomised trial[ J ]. Lancet ,2004,363:2022-2031.
